Replies to post #1608 on Cannabis Investment Club

[JohnCM]

JAY-Z’s new Monogram cannabis unboxed and reviewed

By David Downs
January 14, 2021
Leafly

I got 99 problems but JAY-Z’s weed ain’t one.

The 22-time Grammy-winning rapper debuts in California’s adult-use marijuana market this year with a premium-priced luxury weed brand—Monogram.

The actual herb quality varies and the price point attracts haters. But JAY-Z is a dime bags-to-riches American icon. He’s New York royalty and the owner of Roc Nation.

Beyonce’s husband commands legions of fans with cash and humble dreams to buy up not only the weed but the backstory, and even fresh stock in the company.

So fresh and so clean-clean: Monogram makes a serious first impression.

This January, Leafly reviewed:

2 grams of the “No. 03” flower ($40+tax)
2 grams of the “No. 01” flower ($40+tax)
a 1.5-gram “handroll” ($50+tax)
And the No. 96 “loosies” pre-roll 4-pack ($40)

The loosies were mediocre, the handroll and No. 01 flower came out satisfactory, and the No. 03 flower took the throne. All of it was a serviceable first effort from a celebrity brand.

Monogram’s naming system

Grown indoors in San Jose, CA, Monogram eschews strain names and THC scores. Instead, strains become numbers and potency is either “light,” “medium,” or “heavy.”

As a consumer, this is not helpful.

The No. 01 seems like an OG Kush and the No. 03 resembles an exotic Cookies cross. But how do lovers of OGs and Gelatos find those on shelves?

The Leafly Strain of the Year 2020 is—Runtz!

It’s just like wine: Cannabis strain parentage brings along an audience.

Monogram jettisons that brand value.

Also, people like their THC scores. Yes—some lab fudge scores. Yes—THC does not tell the whole story, but it’s better than nothing. Maybe label it a “No. 01, medium,” but stick the details on social media, or something.

Monogram No. 01 details

Monogram No. 1 close up shows quality. Anyhoo—the No. 01 medium smelled like an OG cross, and looked, tasted, and felt like one: a hybrid body-buzzing, chatty, sensory-enhancer. Not Watch the Throne-level, but solid, A-grade indoor. Respect.

Monogram No. 03 details

Monogram No. 3 could be Kush Mints. The “No. 03, heavy” does earn the throne.

It looked icy and an exotic white-green-purple, with a complex, sweet, cake, and fuel smell. The No. 03 nugs felt hyper-dense and powdery with trichomes. The ground aroma hit spicy, sweet, scrumptious, and cherry. It had a cherry ice cream taste and moderately heavy effects with crazy appetite stimulation.

The No. 03 earns the title of “luxury,” and you pay for it—$40 plus tax for two grams.

Monogram 1.5-gram handroll details

The Monogram handroll is a bat. You’ll feel Shawn Carter’s style in the black handroll carrying case and the hand-crafted fatty inside.

Big and black, the size impresses. It conjures the doinks that pot growers roll with pounds sitting around. “Oh, you fancy, huh?”

The downside: Half the terpenes—the aromatic molecules that give the bud its character—had left the building. This pre-roll still smelled better than the industry average, but that’s not saying much.

Signs of high quality: Nugs, not dry shake, went into this joint, and the flower wasn’t machine-ground. The dry hit tasted mild, piney, and lemony. It burned fine and pulled fine—inoffensive and serviceable in every way.

Real weed heads don’t pay $50 for 1.5 grams, as stoners can roll their own. However, this’ll make a great gift for the college buddy you listened to The Black Album with. Sales data show a growing percentage of customers willing to pay $80 and up for an eighth-ounce of weed.

Monogram loosies No. 88 four-pack. Here we’ve arrived at the weakest link, and it’s still not bad. The No. 96 loosies are four small joints each in a black case—great for a spaced beach meet-up. Folks can smoke their own, ‘cus don’t pass that shit right now.

Sadly, the terps here were industry-standard M.I.A.: missing in action. The joint tube didn’t harbor any great smells, the weed smoked neutral, like the usual house pre-rolls around the Bay. It wasn’t harsh or bad-tasting, just forgettable.

The story behind the bud

But here’s the thing: When you buy and smoke Monogram, you’re not just buying herb, you’re also buying a story. The brand garnered mentions on Saturday Night Live and The Tonight Show Starring Jimmy Fallon, and Instagram features by Jadakiss.

Carter started working with major California licensee Caliva in July 2019. He’s Monogram’s Chief Visionary Officer, with a reported 50% stake in the brand.

Both Caliva, Monogram, and a dozen-plus brands now reside in shell company “The Parent Company.” They’re aiming for the crown of “Largest publicly traded cannabis company in California.”

Selling weed, and stock

Look beyond the trees—this is a paper play. The Federal Reserve’s interest rates make money nearly free, and amateur day traders feel frothy.

Not only can you buy JAY-Z’s weed, you can buy securities in The Parent Company’s parent company, Subversive Capital Acquisition Corp. Subversive is a so-called blank-check company (called a SPAC) and it explicitly aims to consolidate or roll up cannabis brands in California, and beyond:

Subversive raised $75 million on the Canadian exchange NEO. JAY-Z got 5 million shares of The Parent Company, while Roc Nation gets $25 million in stock and a $7.5 million annual fee.

The four-month-old “SBVCF” security also trades in the US. Entertainers Rihanna, Meek Mill, Yo Gotti, and DJ Khaled are reported investors.
According to the Wall Street Journal on Jan. 14., early SPAC investors like JAY-Z carry little risk and can take major profits.

“It’s a free lunch—there’s no way around it,” New York University assistant law professor Michael Ohlrogge told the WSJ.

And late investors end up holding the bag. Instagram commenters talk up SBVCF, but buyer beware: this is an “over-the-counter,” four-month-old stock—untested and volatile.

All of which is to say: Your relationship to Monogram will color your enjoyment of it.

In one corner, cash-strapped, legacy growers reflexively hate the new competition. In the other corner, amateur stock pickers get high on their own supply.

(Disclosure: I own zero stock in or positions on SBVCF; I lost my own 401(k) password.)

The bottom line

Monogram isn’t for true players, but the true players are disappearing—melting icebergs in the warming sea of legal weed.

Mainstream Grammy-watchers get to feel fancy with Monogram this winter, and Jigga’s partner Caliva stands to deliver.

Caliva processed 1.5 million legal weed transactions in California in 2020 alone. Monogram is currently sold out. You can’t knock this hustle.

[JohnCM]

TGIFF
1933 Industries Inc.
Ordinary Shares
0.0755
0.00426

5.98%

0.074 / 0.0761 (30631 x 78945)

OTC DISCLOSURE & NEWS SERVICE
1933 Industries Reports First Quarter 2021 Financial Results
Press Release | 12/29/2020

A 60% decrease in net loss and an 80% improvement in adjusted EBITDA bring the Company closer to profitability

VANCOUVER, BC / ACCESSWIRE / December 29, 2020 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF)(OTCQX:TGIFF), a vertically integrated cannabis consumer packaged goods company, is pleased to announce its first quarter ("Q1 2021") financial results for the period ended October 31, 2020. All amounts expressed are in Canadian dollars.

Q1 2010 Financial Highlights

Fiscal 2020 Consolidated Results
Q1 2021
(Oct 31, 2020)
Q4 2020
(July 31, 2020)
Q1 2020
(Oct 31, 2019)
Revenues
$2,687,516
$2,388,010
$3,881,183
Gross margin
$728,700
$63,177
$2,085,104
Cash balance
$2,044,574
$2,761,542
$14,872,277
Expenses
$3,544,687
$5,426,639
$5,901,402
Net loss
($2,818,577)
($7,236,277)
($3,816,298)
Comprehensive loss
($2,929,123)
($8,426,832)
($3,962,300)
Adjusted EBITDA loss
($1,351,212)
($7,196,520)
($1,827,699)
Basic and diluted loss per share
($0.01)
($0.03)
($0.01)
Total assets
$45,431,525
$46,584,470
$61,358,608
Total liabilities
$26,714,275
$27,132,288
$26,033,715
Equity
$18,717,250
$19,452,182
$35,324,893

Operating Results

During the reporting period, total revenues were $2.7 million, a 13% increase from the previous quarter. The increase was attributed to the Company's launch of cannabis flower and pre-rolls in the Nevada market. With improved plant genetics and in-demand strains, the Company's new saleable flower and cannabis products have sold out after each harvest, as the demand for craft cannabis flower remains strong in Nevada, despite the loss of tourism due to the COVID-19 pandemic.

Gross margin was $729,000 or 27%, compared to $63,000 or 3% during Q4 2020. The increase in gross margin from the prior quarter is due to the Company's enhanced ability to produce saleable flower and biomass from its cultivation facility.

General and administration expenses in Q1 2021 were $1.2 million, compared to $2.0 million during Q4 2020 and $2.3 million during Q1 2020. This change over the prior quarter represents managements' commitment to making strategic reductions to streamline operations with the overarching goal of reaching profitability in the near future.

Expenses were $3.5 million for Q1 2021, a 35% decrease from $5.4 million in Q4 2020 and a 40% decrease from $5.9 million for Q1 2020. The Company reduced expenses in all areas, including management and consulting fees, wages and benefits. It is management's priority to continue to reduce costs to meet its financial goals.

Net loss from continuing operations was $2.8 million or $0.01 per share for Q1 2021. The net loss for Q1 2021 represents a 61% improvement from a $7.2 million loss in Q4 2020 and a 26% decrease from losses incurred in Q1 2020.

Adjusted EBITDA loss was $1.4 million, an 81% improvement from $7.2 million in Q4 2020, and a 26% improvement from $1.8 million for Q1 2020.

The Company's licensed cultivation and production subsidiary, Alternative Medicine Association ("AMA") reported revenues of $1.6 million and gross margin of $164,000. Infused MFG, a subsidiary focused on the manufacturing of proprietary hemp derived CBD products under the Canna Hemp™ brand, reported revenues of $1.1 million and gross margin of $565,000.

Balance Sheet

Cash at October 31, 2020 was $2.0 million, compared to $2.8 million at July 31, 2020, a decrease of 29%. Subsequent to the reporting period, the Company completed a private placement financing for proceeds totalling $918,720.

Total assets were $45.4 million during Q1 2021, compared to $46.6 million during the previous quarter, a decrease of 3%.

Working capital for Q1 2021 was a deficiency of $5.0 million, compared to a working capital surplus of $6.1 million for Q4 2020, due to the reclassification of $10.0 million convertible debentures from long term to current liabilities as they mature on September 14, 2021. The Company anticipates that the convertible debentures will most likely be converted into common shares as per recent amendments, (see news release dated June. 29, 2020).